Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a classical glycolytic enzyme that is involved in cellular energy production and has important housekeeping functions. We used the natural prooxidant and proatherogenic molecule oxidized low-density lipoprotein (OxLDL) to determine a potential link between OxLDL-promoted oxidative stress, GAPDH expression, and smooth muscle cell energy metabolism. OxLDL but not native LDL (nLDL) produced a 60% to 100% dose-and time-dependent reduction of GAPDH protein. OxLDL increased reactive oxygen species (ROS) formation, including rapid elevation of H 2 O 2 levels. OxLDL decreased intracellular catalase expression, likely contributing to the increase in H 2 O 2 . Antioxidants, anti-CD36 receptor antibody, NADPH oxidase, or lipoxygenase blockers decreased OxLDL-specific ROS and prevented GAPDH downregulation. 12/15-Lipoxygenase or p47phox deficiency resulted in attenuation of GAPDH downregulation, but 5-lipoxygenase suppression had no effect. OxLDL or exogenous H 2 O 2 oxidized GAPDH thiols, decreasing GAPDH protein half-life and increasing GAPDH sensitivity to proteasome-mediated protein degradation in vitro. OxLDL-or small interfering RNA-specific downregulation of GAPDH resulted in 65% reduction in glycolysis rate and 82% decrease in ATP levels. In conclusion, our data demonstrate that OxLDL downregulated GAPDH via a H 2 O 2 -dependent decrease in protein stability. GAPDH protein damage resulted in marked depletion of cellular ATP levels. Our data have important implications for understanding the metabolic effect of OxLDL on the vessel wall and mechanism of atherogenesis. (Circ Res. 2006;99:191-200.) Key Words: reactive oxygen species Ⅲ low-density lipoprotein Ⅲ energy metabolism Ⅲ vascular smooth muscle
G lyceraldehyde-3-phosphate dehydrogenase (GAPDH) (EC 1.2.1.12) is a glycolytic enzyme involved in energy production and is one of the most abundant cellular proteins. GAPDH is constitutively expressed in different cells and is viewed as an important housekeeping molecule. However, it has become clear that the role of GAPDH is not restricted to its pivotal glycolytic function. Indeed, GAPDH regulates multiple other processes, including membrane fusion, nuclear RNA transport, and DNA replication and repair. 1 Increasing evidence suggests that GAPDH is a preferential target for oxidative stress. Nitric oxide (NO) and reactive oxygen species (ROS)-mediated oxidation of GAPDH thiols (S-thiolation) and subsequent inhibition of enzyme activity have been described in colon epithelial cells during inflammatory bowel disease. 2 Wentzel et al 3 demonstrated that diabetic embryopathy in the rat is associated with the inhibition of GAPDH activity and a decrease in GAPDH mRNA and that this effect is blunted by the antioxidant N-acetylcysteine. Taken together, these observations indicate a high sensitivity of GAPDH to cell redox status and potential involvement of this enzyme in oxidative stress-promoted events.
Oxidized low-density lipoprotein (OxLDL) is a powerful natural prooxidant derived in vivo from nLDL by cellmediated oxidation. 4 OxLDL is a key proatherogenic agent 5 that induces, as we have shown, an increase in ROS formation, specific alterations in gene/protein expression, and apoptosis of vascular smooth muscle cells. 6 -9 We designed this study to determine a potential link between OxLDLspecific increase in ROS, GAPDH expression, and human aortic smooth muscle cell (HASMC) energy metabolism. Our findings indicate dramatic OxLDL-induced downregulation of GAPDH via a redox-dependent signal pathway, resulting in depletion of cellular energy stores. These results provide a potential mechanism for understanding metabolic alterations of the vasculature during the process of atherogenesis. mation of intracellular ROS were assessed with 6-carboxy-2Ј,7Јdichlorodihydro-fluorescein diacetate (CDC-H 2 F), hydroethidine, and Amplex Red kit (all from Molecular Probes). GAPDH free thiol status was measured by labeling of cell extracts with the thiolsensitive fluorescent dye fluorescein-5-maleimide (Molecular Probes), and metabolic labeling of HASMC was performed with EXPRE 35 S 35 S Protein Labeling Mix (Perkin Elmer) followed by immunoprecipitation with anti-GAPDH (Chemicon) or anti-␤-actin (Sigma) antibody. An expanded Materials and Methods section containing details regarding ROS measurements, GAPDH purification, proteasome protein-degradation assay, and use of small interfering RNA (siRNA), as well as Figures I through III, are given in the data supplement, available at http://circres.ahajournals.org.
Results

OxLDL Downregulates GAPDH Protein
Confluent (80% to 90%) HASMC were treated with 60 g/mL OxLDL or native LDL (nLDL) (control) for 0 to 24 hours or incubated in serum-free media (SFM). No change in GAPDH expression was found after cell treatment with nLDL or SFM; in contrast, cell incubation with OxLDL time-dependently downregulated GAPDH protein ( Figure  1A ). GAPDH protein level was reduced in OxLDL-treated cells to 68Ϯ15% and 33Ϯ10% compared with control at 9 and 15 hours, respectively, and GAPDH expression at 24 hours was virtually not detectable.
HASMC treatment by LDLs for 15 hours was selected for generation of dose-response curves and to assess effects of antioxidants. For dose-response experiments, HASMC were treated with 0 to 100 g/mL OxLDL or nLDL and GAPDH expression was analyzed by immunoblotting. Sixty micrograms per milliliter OxLDL decreased GAPDH levels to 38Ϯ11%, and 80 g/mL OxLDL downregulated GAPDH to 25Ϯ3%. OxLDL (20 to 100 g/mL) produced no changes in protein levels of other housekeeping proteins ␤-actin and ␤-tubulin ( Figure 1B ). However, we noted that treatment of HASMC with highly OxLDL (Ͼ50 nmol malondialdehyde per milligram protein) slightly decreased ␤-actin levels (15Ϯ5% compared with nLDL-treated cells), as evidenced by immunoblotting, together with marked downregulation of GAPDH protein levels.
Immunoblotting data obtained with mouse monoclonal anti-GAPDH antibody were further confirmed with rabbit polyclonal anti-GAPDH antibody (data not shown). We also examined the efficiency of the recognition of potentially oxidized antigen (GAPDH) by cognitive antibody (mouse anti-GAPDH) in a routine Western analysis. Purified chicken muscle GAPDH (0.1 mg/mL; Sigma) was directly oxidized by 1.5 mmol/L H 2 O 2 , and an aliquot of oxidized and untreated GAPDH (control) were analyzed by immunoblotting. No differences were found between band density of oxidized GAPDH and control (data not shown). Although the possibility remains that there is a loss of immunoreactivity independent of reduced expression of the GAPDH protein. This appears unlikely in view of our results comparing immunoreactivity of oxidized and nonoxidized GAPDH using 2 different epitope-specific anti-GAPDH antibodies.
GAPDH gene expression was analyzed by Northern blotting. In time-course experiments, GAPDH protein was decreased after 9 hours of OxLDL treatment, and for this period (0 to 9 hours), GAPDH mRNA levels were not changed significantly compared with nLDL ( Figure 1C ). However, longer incubation with OxLDL (15 to 24 hours) produced a slight decrease of GAPDH mRNA (18Ϯ5% at 24 hours).
Antioxidants Suppress OxLDL-Specific Peroxides, Decrease Superoxides, and Prevent Downregulation of GAPDH
Because OxLDL signaling can involve ROS, 10 we assessed formation of intracellular peroxides and superoxides in LDLtreated HASMC with the peroxide-sensitive dye CDC-H 2 F and the superoxide-specific dye hydroethidine (HE). Both oxidized and native LDL (60 g/mL) increased cell peroxides time dependently up to 9 hours of treatment. For 2 to 6 hours of incubation, OxLDL produced 40% to 70% more peroxides than nLDL, but longer treatments resulted in no difference between peroxide levels induced by OxLDL and control (see supplemental Figure IA ). Unlike peroxide formation, superoxide level was significantly higher in cells treated with OxLDL versus nLDL for all time points up to 30 hours. OxLDL increased peroxides dose dependently (20 to 80 g/mL), with a peak formation at 3 to 4 hours. OxLDL- Pretreatment with the water-soluble vitamin E derivative Trolox (0.25 mmol/L) or antioxidant Tiron (1 mmol/L) dramatically reduced basal and nLDL-induced peroxides, with complete elimination of OxLDL-specific peroxides (Figure 2A ). In contrast, antioxidants were less efficient in inhibition of cell superoxides induced by OxLDL; both nLDL-or OxLDL-induced superoxides were equally suppressed by antioxidants ( Figure 2B ). Trolox or Tiron completely prevented OxLDL-specific decrease in GAPDH (Figure 2C ). Based on this data, we concluded that ROS mediate the OxLDL-specific GAPDH decrease.
CD36 Scavenger Receptor, 12/15-Lipoxygenase, and NADPH Oxidase Mediate OxLDL-Induced ROS Increase and GAPDH Downregulation
The CD36 scavenger receptor mediates the uptake of OxLDL, allowing OxLDL-specific intracellular signaling and development of atherosclerosis. 11 Using real time PCR we confirmed the presence of CD36 mRNA in HASMC and one unique protein band immunogenic to CD36 antibody (MWϭ90Ϯ7 kDa, nϭ3) was detected in cell lysates by immunoblotting (data not shown). To verify the potential involvement of CD36 receptor in OxLDL-specific ROS increase and GAPDH downregulation we used mouse FA6 -152 anti-CD36 blocking antibody (Immunotech, Cedex, France), a specific inhibitor of CD36-dependent OxLDL uptake. 11 We found that anti-CD36 antibody (20 g/mL) decreased OxLDL-specific increase in peroxide and superoxide formation, whereas pretreatment with nonspecific antibody (20 g/mL normal mouse IgG) had no effect (see supplemental Figure II ). Antibody-specific inhibition of CD36 scavenger receptor resulted in complete inhibition of OxLDL-induced GAPDH decrease ( Figure 3A) .
We used allopurinol, the xanthine oxidase inhibitor; NS-398, the specific blocker of cyclooxygenase-2; indomethacin, the nonspecific blocker of cyclooxygenase-1 and cyclooxygenase-2; and rotenone, the inhibitor of mitochondrial complex I, to study potential involvement of these ROS producing systems in OxLDL-dependent increase in HASMC peroxides and superoxides. Preincubation of HASMC with 100 mol/L allopurinol, 10 mol/L NS-398, or 10 mol/L indomethacin did not block OxLDL-specific peroxide or superoxide formation or downregulation of GAPDH, and rotenone was toxic at concentrations of 10 and 100 mol/L (data not shown).
Lipoxygenases (LOXs), such as 5-LOX, which is a key enzyme in leukotriene production, and 12/15-LOX are a family of lipid peroxidizing enzymes that are another source of ROS in the vasculature. 12 We verified the presence of 5and 12/15-LOX proteins and corresponding enzyme activities in HASMC (data not shown). We found that the LOX inhibitor AA-861 (5 mol/L) markedly reduced OxLDLinduced ROS production (supplemental Figure II) . The same dose of AA-861 completely blocked OxLDL downregulation of GAPDH ( Figure 3B ). To identify the LOX form that mediates OxLDL-induced ROS production and GAPDH downregulation, we used 5-LOX-specific and nonspecific (control) siRNA-treated HASMC and vascular smooth muscle cells (SMC) obtained from 12/15-LOX-deficient mice 13 and wild-type mice (control). All methods involving animals were approved by the Institutional Animal Care and Use Committee (IACUC) of Tulane University Health Sciences Center. siRNA-mediated 5-LOX protein decrease was 65% as measured by immunoblotting analysis ( Figure 3D ), and there was a similar decrease in 5-LOX mRNA levels as measured by real-time PCR (data not shown). We found that 12/15-LOX deficiency resulted in a 62Ϯ7% reduction of OxLDLinduced peroxides; however, 5-LOX suppression had no effect (supplemental Figure III) . OxLDL-induced downregulation of GAPDH was significantly blunted in 12/15-LOX Ϫ/Ϫ vascular SMC (54Ϯ14% inhibition compared with wildtype), whereas 5-LOX suppression had no blocking effect on OxLDL-induced GAPDH downregulation ( Figure 3E ).
The membrane-bound NADPH oxidase is a predominant source of ROS in multiple pathophysiological conditions in vascular smooth muscle. 14 We found that apocynin (50 mol/L), a potent and selective inhibitor of NADPH oxidase, and the structurally unrelated NADPH oxidase blocker AEBSF (1 mmol/L) were less efficient in suppression of OxLDL-specific ROS compared with AA-861 (supplemental Figure II ). NADPH oxidase blockers only partially suppressed downregulation of GAPDH ( Figure 3C ). p47phox is a critical subunit of the NADPH oxidase, and a null mutation of this gene resulted in attenuation of superoxide production in SMC and suppression of atherosclerosis. 15 To verify our data obtained with NADPH oxidase inhibitors, we measured peroxides and GAPDH protein levels in vascular SMC from p47phox Ϫ/Ϫ or wild-type (control) mice exposed to nLDL or OxLDL. We found that p47phox Ϫ/Ϫ cells produce 82% less peroxides in response to OxLDL compared with wild type (supplemental Figure III) . p47phox deficiency completely blocked OxLDL-induced GAPDH downregulation ( Figure 3F ). These data suggest involvement of the CD36 receptor, 12/15-LOX, and NADPH oxidase in ROS formation and OxLDL-specific GAPDH downregulation. 16 and, therefore, could be involved in ROS-mediated GAPDH downregulation. We measured specific H 2 O 2 release from LDL-exposed cells with/without pretreatment with Trolox (0.25 mmol/L), specific H 2 O 2 scavengers catalase (10 kU/mL), or polyethylene glycol-coupled catalase (PEGcatalase) (1 kU/mL) using the Amplex Red assay. OxLDL (60 g/mL, 3 hours) significantly increased H 2 O 2 levels compared with nLDL or SFM ( Figure 4A ). Pretreatment with antioxidant or catalase efficiently suppressed OxLDLinduced H 2 O 2 formation to below basal levels. After calibration of the Amplex Red signal with standards (H 2 O 2 , 0 to 1000 mol/L), we estimated that the OxLDL-specific increase in cellular H 2 O 2 level corresponds to 350 to 450 mol/L H 2 O 2 (data not shown). This is consistent with reports showing that oxidative stress enhanced cellular H 2 O 2 concentration in vivo to the submillimolar range. 17 Therefore, we examined GAPDH expression in response to similar doses of exogenous H 2 O 2 . We found that HASMC incubation with H 2 O 2 (225 to 450 mol/L, 16 hours) resulted in a downregulation of GAPDH and that this effect was dose dependent ( Figure 4B ).
H 2 O 2 Scavengers Completely Block OxLDL-Specific GAPDH Downregulation, and Exogenous H 2 O 2 Downregulates GAPDH
Based on these data, we hypothesized that OxLDL-specific increase in H 2 O 2 is critical for subsequent GAPDH protein suppression and verified this hypothesis using H 2 O 2 scavengers (catalase and PEG-catalase) and superoxide scavengers (superoxide dismutase [SOD] and PEG-SOD). Only catalases completely blocked OxLDL-induced downregulation of GAPDH ( Figure 4C and 4D). The blocking effect of SOD was partial: GAPDH levels still decreased in OxLDL-treated cells compared with nLDL (67Ϯ7% of control, nϭ3, PϽ0.05) after preincubation with this superoxide scavenger. PEG-SOD at 50 U/mL even potentiated GAPDH downregulation and was toxic at higher concentrations. This data suggested that OxLDL-specific increase in H 2 O 2 is responsible for GAPDH downregulation.
OxLDL Rapidly Decreases Catalase Activity in HASMC and Does Not Alter SOD Activity
Two major antioxidant enzyme systems protect cells from oxidative stress by maintaining safe levels of ROS: SODs, Figure 3 . CD36 scavenger receptor, 12/15-LOX, and NADPH oxidase mediate downregulation of GAPDH. HASMC were stimulated by 60 g/mL LDLs with/without pretreatment with 20 g/mL anti-CD36 blocking antibody or normal mouse IgG (A) or 5 mol/L LOX inhibitor AA-861 (B) or 50 mol/L NADPH oxidase blocker apocynin or 1 mmol/L AEBSF (C), and GAPDH protein levels were measured by immunoblotting with ␤-actin as loading control. Wild-type or 12/15-LOX-deficient (E) or p47phox-deficient (F) mouse vascular SMC were stimulated by 60 g/mL LDLs, and GAPDH protein levels were measured by immunoblotting. HASMC were transfected with siGENOME SMART 5-LOX siRNA or Silencer 6-carboxyfluorescein (FAM)labeled negative control siRNA by pulse electroporation and, after 48 hours, used for immunoblotting analysis with 5-LOX antibody (D) or treated by LDLs followed by immunoblotting with anti-GAPDH or anti-␤-actin antibody (E). *PϽ0.05, ‡PϾ0.05 vs control (nLDL).
enzymes that catalyze conversion of superoxides to H 2 O 2 including intracellular (Mn-SOD, Cu/Zn-SOD) and extracellular (EC-SOD) forms and catalase. 18 To clarify the potential mechanism of OxLDL-induced H 2 O 2 elevation, we measured the activity and protein levels of SODs and catalase in HASMC treated by OxLDL.
Immunoblotting analysis showed that the relative amount of catalase was decreased by 58Ϯ5% by OxLDL treatment compared with nLDL, but Mn-SOD protein level was not changed ( Figure 5A and 5B) . Similarly, the functional activity of catalase was significantly reduced ( Figure 5C ). However, activity of intracellular SOD, as assessed by Cayman Chemical assay and in situ SOD activity detection, was not different between OxLDL-and nLDL-treated cells (data not shown). Additionally, Western blotting revealed that OxLDL did not alter expression of Cu/Zn-SOD (data not shown). We detected activity of an EC-SOD-like protein in conditioned media from LDL-treated cells using in situ assay and found that this activity also was unregulated by OxLDL (data not shown). These data suggest that the reduction in catalase activity and the maintenance of SOD activity could contribute to the increase in intracellular H 2 O 2 in response to OxLDL.
OxLDL or H 2 O 2 Oxidize GAPDH Thiols and Decrease Protein Stability
The GAPDH molecule has 3 easily oxidized SH groups and 2 of them (Cys149 and Cys153) are essential for GAPDH catalytic activity. 19 We measured GAPDH thiol status following cell exposure to OxLDL or H 2 O 2 . GAPDH-labeling OxLDL (60 g/mL) (or nLDL) was added to cells at time 0 with/without preincubation with Trolox (0.25 mmol/L) or H 2 O 2 scavenger catalase (10 kU/mL) or PEG-catalase (1 kU/mL), and, after 3 hours, cells were loaded by Amplex Red with 0.2 U/mL horseradish peroxidase. Fluorescence signal was measured in microplate reader set at an excitation wavelength of 535Ϯ20 nm and emission wavelength of 590Ϯ35 nm. B, Exogenous H 2 O 2 mimics OxLDL-specific GAPDH downregulation. HASMC were incubated with H 2 O 2 (0 to 450 mol/L, 15 hours), and GAPDH protein levels were measured by immunoblotting with ␤-actin as loading control. *PϽ0.05 vs untreated cells. C and D, H 2 O 2 scavengers completely block downregulation of GAPDH. HASMC were treated by LDLs (60 g/mL) with or without preincubation with superoxide scavenger SOD (0.5 kU/mL) or PEG-SOD (0.05 kU/mL) or H 2 O 2 scavenger catalase (25 kU/mL) or PEG-catalase (1 kU/mL), and GAPDH protein levels were measured by immunoblotting. Figure 5 . OxLDL rapidly suppresses catalase protein and activity. HASMC were treated with LDLs (60 g/mL, 3 hours), and cell lysates were prepared and used in immunoblotting experiments or activity assay. A, Representative Western blots. B, Immunoblotting ratio data. C, Cell lysates (or standards) were mixed with H 2 O 2 plus methanol, and catalase-induced formaldehyde formation was measured spectrophotometrically (A 540 ) with 4-amino-3-hydrazino-5-mercapto-1, 2, 4,-triazole. One unit of catalase activity was defined as the amount of enzyme that would cause the formation of 1.0 nmol/L formaldehyde per minute at 25°C. efficiency with the thiol-sensitive dye fluorescein-5maleimide was dramatically decreased following treatment with OxLDL (60 g/mL, 3 hours) or, similarly, after incubation with H 2 O 2 (400 mol/L, 3 hours) without alteration of GAPDH protein levels ( Figure 6 ).
In theory, GAPDH thiol (R-S-H) modification by an oxidant can include: (1) formation of inter-or intramolecular disulphide bands (R-S-S-R); (2) formation of mixed disulphides with a small intracellular thiol, glutathione (R-S-S-R 2 ); or (3) direct oxidation of the Cys thiol groups to sulfenic acid (R-S-O-H). To address the first possibility, we used nonreducing gel electrophoresis to examine whether formation of an intramolecular disulphide bond or a bond between 2 molecules of GAPDH resulted in altered protein migration by nonreducing SDS-PAGE. Neither H 2 O 2 nor OxLDL treatment of cells resulted in altered GAPDH electrophoretic mobility (data not shown). To address the second possibility, we examined GAPDH thiol oxidation by H 2 O 2 in cell-free conditions and examined the potential protein glutathionylation by immunoblotting. We found no significant difference in GAPDH glutathionylation level between oxidant-treated cells and controls (data not shown). Moreover, GAPDH oxidized in glutathione-free conditions (Figure 6 , top) has an identical thiol pattern to GAPDH oxidized by cell treatment with oxidant ( Figure 6 , bottom). Little and O'Brien clearly demonstrated that H 2 O 2 oxidizes GAPDH thiols via formation of sulfenic acid, 20 and our experiments are consistent with formation of -S-O-H groups as the most likely mechanism of GAPDH thiol oxidation by OxLDL.
In view of the lack of the effect of OxLDL on GAPDH mRNA levels, we performed pulse-chase labeling experiments to assess the potential effect of OxLDL or H 2 O 2 on GAPDH protein stability. As shown in Figure 7A and 7B, either OxLDL or H 2 O 2 markedly decreased GAPDH protein half-life (to 18Ϯ2 and 4Ϯ1 hours, respectively, compared with Ͼ24 hours in controls).
Proteasome Inhibitors MG-132 and Lactacystin Do Not Inhibit GAPDH Downregulation In Vivo, but Oxidized GAPDH Has Increased Sensitivity to Proteasome-Mediated Degradation In Vitro
Because it has been shown that H 2 O 2 -mediated protein oxidation "marks" proteins for preferential utilization in protein-degradation pathways, 21 we compared the sensitivity of the oxidized and nonoxidized GAPDH to proteasomemediated degradation in vitro. GAPDH purified from OxLDL-treated HASMC was completely degraded after 2 hours of incubation in a proteasome protein-degradation assay; however, protein level of GAPDH from control cells was not changed. Similarly, H 2 O 2 -oxidized GAPDH or GAPDH purified from H 2 O 2 -exposed cells was degraded faster than control protein ( Figure 7C ).
However, interestingly, pretreatment of cells with the proteasome inhibitor MG-132 (10 mol/L) or lactacystin (10 mol/L) did not inhibit OxLDL-induced downregulation of GAPDH ( Figure 7D ), suggesting that alternative nonproteasome-dependent pathway(s) are primarily responsible for OxLDL-induced degradation of GAPDH protein in vivo.
OxLDL-Specific GAPDH Downregulation Decreases Cell Glycolysis Rate and ATP Stores
We assessed energy metabolism in LDL-treated cells by measurement of glycolysis rates and total ATP levels. Glucose usage was inhibited by 65Ϯ7% in HASMC treated with OxLDL (60 g/mL, 16 hours) compared with cells incubated in lipid-free media, whereas incubation with nonoxidized lipoprotein slightly stimulated cell glycolysis ( Figure 8A) .
To determine whether downregulation of GAPDH expression sufficed to reduce glycolysis rates, we used GAPDHspecific siRNA to downregulate GAPDH. As shown in Figure 8D , 50 nmol/L anti-GAPDH siRNA markedly reduced HASMC glycolysis rate. In addition, total ATP levels were reduced by 82Ϯ4% in OxLDL-treated cells ( Figure 8B ) and by 89Ϯ6% in siRNA-treated cells ( Figure 8E ) compared with control. These data indicate that GAPDH downregulation results in dramatic reduction of cell glycolysis rates and ATP depletion.
Discussion
GAPDH plays a key role in energy metabolism by conversion of glyceraldehyde-3-phosphate to 1, 3-bisphospho-glycerate in the glycolytic pathway. GAPDH has been referred to as a housekeeping protein based on the classical view that GAPDH expression remains relatively constant under changing cellular conditions. However, GAPDH is now known to contribute to a number of cellular functions unrelated to glycolysis that include nuclear RNA export and DNA replication and repair, exocytotic membrane fusion, cytoskeletal organization and phosphotransferase activity, apoptosis, and viral pathogenesis. 1 In the present study, we explored the potential effect of oxidative stress on GAPDH expression using a model with or from cells incubated with LDLs (60 g/mL, 3 to 9 hours) or control protein (intact chicken muscle GAPDH) was labeled by the thiol-sensitive fluorescent dye fluorescein-5maleimide (F5M). Samples and control were separated on the 5/12% PAGE, and F5M-labeled protein bands were visualized and documented under UV light. Gel was immediately submitted for immunoblotting with GAPDH antibody to identify specific protein band. significant physiological relevance, namely, the effects of OxLDL, a critically important proatherogenic agent 4 -6,9,22 on one of its main cellular targets, namely vascular smooth muscle. We have previously shown that OxLDL is localized to vascular smooth muscle in both early and advanced human atherosclerotic plaques 22 and that OxLDL downregulates expression of insulin-like growth factor-1 (IGF-1) and its receptor in vascular smooth muscle. 6, 7, 8 Here, we report that OxLDL markedly time-and dose-dependently downregulates GAPDH expression in HASMC via a redox-dependent mechanism, leading to a reduction in protein stability. Under the same experimental conditions, protein levels of other housekeeping molecules, namely ␤-actin and ␤-tubulin (data not shown) were not changed.
To identify mechanisms mediating OxLDL downregulation of GAPDH, we measured ROS formation in LDL-treated HASMC and demonstrated OxLDL-specific increases in total peroxides, superoxides, and H 2 O 2 . Antioxidants (Trolox, Tiron), LOX inhibitor (AA-861), and anti-CD36 receptor antibody suppressed both OxLDL-specific increase in ROS and downregulation of GAPDH and vice versa: inhibitors with no effect on ROS (allopurinol, indomethacin, NS-398) failed to prevent GAPDH downregulation. These results strongly suggest that OxLDL-generated ROS are critically important in mediating the downregulation of GAPDH.
We have recently shown, using a proteomic screen, that the CD36 receptor is markedly upregulated in HASMC exposed to OxLDL. 7 This receptor is responsible for the uptake of approximately 80% of modified LDL by smooth muscle cells. 23 In the present study, we report that the CD36 receptor is essential for both OxLDL-induced ROS formation and GAPDH downregulation. Our data suggest that OxLDL (1 mmol/L). At the end of each chase period, the cells were harvested; cell extracts were obtained and subjected to immunoprecipitation with anti-GAPDH or anti-␤-actin antibody. Immunocomplexes were analyzed after electrophoresis in 5/12% SDS-PAGE, followed by gel drying and scanning with a phosphoimager. C, Oxidized GAPDH has increased sensitivity to proteasomemediated degradation. Chicken muscle GAPDH oxidized by H 2 O 2 in vitro or GAPDH purified from H 2 O 2 -or LDL-treated HASMC was incubated with proteasome protein-degradation assay with/without proteasome inhibitor MG-132 (50 mol/L); aliquots were taken at time points indicated and analyzed by immunoblotting with anti-GAPDH antibody. D, HASMC were preincubated with proteasome inhibitor MG-132 (10 mol/L) or lactacystin (10 mol/L) for 1 hour and then exposed to LDLs (60 g/mL), and GAPDH protein levels were measured by immunoblotting with ␤-actin as loading control.
binding to CD36 results in enhanced ROS generation by LOX/NADPH oxidase, consistent with a novel functional relationship between CD36 and oxidases to generate ROS in HASMC.
ROS may be generated by different intracellular sources. The membrane-bound NADPH oxidase is a predominant source of ROS in multiple pathophysiological conditions in vascular smooth muscle. 14 For instance, NADPH oxidase plays an essential role in angiotensin II-specific ROS formation in vascular smooth muscle. 24 5-and 12/15-LOX also contribute to generation of ROS in SMC and 5-LOX or 12/15-LOX deficiency suppressed atherosclerosis in apolipoprotein E-deficient mice. 25, 26 We demonstrated that specific inhibitors of NADPH oxidase assembly decreased OxLDL-specific ROS and partially prevented downregulation of GAPDH and that GAPDH downregulation was completely blocked in p47phox Ϫ/Ϫ vascular SMC. The LOX inhibitor AA-861 and 12/15-LOX deficiency also reduced OxLDL-induced ROS generation and GAPDH downregulation. These data strongly suggest that OxLDL uses at least 2 different oxidases (NADPH oxidase and 12/15-LOX) for generation of ROS and downregulation of GAPDH in response to OxLDL in vascular SMC.
Both total peroxide measurements with CDC-H 2 F and specific H 2 O 2 detection by Amplex Red show that OxLDL quickly enhances cellular H 2 O 2 level. Our previous observation that OxLDL compounds, oxidized fatty acids, could also increase intracellular levels of H 2 O 2 in smooth muscle cells, mediating its cytotoxic effects, 27 is consistent with these data. We report here that H 2 O 2 scavengers, but not scavenging of superoxides, blocked the OxLDL-specific decrease in GAPDH. Furthermore, exogenous H 2 O 2 mimics the effect of OxLDL and dose-dependently downregulates GAPDH. Taken together, these data indicate a major contribution of H 2 O 2 in ROS-mediated GAPDH suppression.
We found that SODs have differential effects on OxLDLspecific GAPDH suppression: SOD acts as a partial blocker, but PEG-SOD is able to slightly potentiate GAPDH suppression. Dual functional roles of SOD (superoxide scavenger/ H 2 O 2 generator) 18 could explain the difference between these effects. PEG-SOD, an enzyme with preferential intracellular distribution, 28 decreases superoxides but also increases H 2 O 2 , which may reach toxic levels in some cellular compartments. In contrast, SOD-dependent H 2 O 2 increase in the extracellular media may be less critical, because of dilution and/or antioxidant activity in conditioned medium. Our data suggest that one mechanism that could contribute to OxLDL-induced H 2 O 2 elevation is the conversion of high levels of superoxides in OxLDL-treated cells into "extra" H 2 O 2 by different active SODs present in HASMC. Our finding that OxLDL suppressed activity of the H 2 O 2 scavenger, catalase, could be an additional mechanism contributing to the increase in cellular H 2 O 2 levels.
Our data indicate that the primary mechanism for OxLDL downregulation of GAPDH is a reduction in protein stability, as shown by pulse-chase labeling experiments. OxLDLinduced GAPDH oxidation, and namely S-thiolation, was likely mediated via an increase in intracellular H 2 O 2 (consistent with previous reports that GAPDH may be oxidized by Figure 8 . OxLDL-or siRNA-specific GAPDH suppression reduces cell glucose usage (A and D) and decreases cellular ATP levels (B and E). A and D, GAPDH suppression reduces cell glucose usage. LDLtreated cells (60 g/mL, 16 hours) (A) or GAPDH siRNA-or negative control siRNA-transfected cells (50 nmol/L, 48 hours after transfection) (D) were incubated with 0.5 Ci/mL radioactive glucose, and aliquots of media were collected at time points indicated. 3 H 2 O was separated from radioactive glucose by the vapor-phase equilibration method, and the radioactivity was analyzed. C, GAPDH siRNA-treated HASMC have decreased GAPDH protein level. Cells were resuspended in 100 L of electroporation Amaxa buffer with 20 to 100 nmol/L Silencer 6-carboxyfluorescein (FAM)-labeled GAPDH siRNA or Silencer FAMlabeled negative control siRNA and pulse electroporated in Amaxa Nucleofector. After 48 hours, GAPDH protein levels were measured by immunoblotting. B and E, GAPDH suppression reduces ATP levels. LDL-treated cells (60 g/mL, 16 hours) (B) or cells 48 hours after transfection with GAPDH siRNA or negative control siRNA (E) were used for ATP concentration measurement with luciferin/luciferase bioluminescent assay. exogenous H 2 O 2 in endothelial cells 19, 29 ) and resulted in a major decrease in GAPDH protein half-life. Thus, oxidized GAPDH protein was less stable than nonoxidized protein, as evidenced by the increased sensitivity of OxLDL-or H 2 O 2oxidized GAPDH to proteasome system-mediated degradation. These data strongly suggest that OxLDL-induced H 2 O 2dependent GAPDH oxidation makes this protein a preferential substrate for cellular protein degradation.
We found that the proteasome inhibitor MG-132 efficiently blocks oxidized GAPDH degradation in vitro ( Figure 7C,  top) ; however, this inhibitor as well as lactacystin failed to prevent OxLDL-specific GAPDH downregulation in HASMC ( Figure 7D ). As reported recently, 4-hydroxy-2nonenal-induced GAPDH degradation in a leukemia cell line was also resistant to pretreatment with MG-132, 30 suggesting that a system other than the ubiquitin-proteasome pathway was responsible for GAPDH degradation in vivo. Because a variety of protein-degradation systems mediate removal of oxidized proteins from the cell, including the proteasome system, 31 a complex process of chaperone-mediated autophagy (lysosomes) 32 and endoplasmic reticulum-associated degradation, 33 identification of specific system(s) that mediate oxidized GAPDH degradation in vivo is an important area for further investigation.
Great variability has been reported for ATP levels within the atherosclerotic arterial wall depending on lesion stage, development of necrosis, the presence of lipoproteins, oxygen availability, and local levels of glucose. 34 Notably, it has been demonstrated that ATP levels were strongly decreased in atherosclerotic lesions that developed in combination with hypercholesterolemia. 35 Consistent with this in vivo study, we report here that there is marked suppression of cell glucose usage and a reduction in levels of ATP in vascular smooth muscle cells exposed to a major proatherogenic molecule, OxLDL. Furthermore, downregulation of GAPDH using siRNA produced equivalent reductions in glycolysis rate and ATP levels. Our data strongly suggest that OxLDLspecific GAPDH downregulation results in inhibition of glycolysis, which, in turn, probably, mediates general ATP depletion. We have also found that OxLDL decreases levels of 1 of the major glycolysis products, L-lactate (S. Sukhanov, unpublished data, 2005) . Our findings suggest that alterations in arterial wall energy homeostasis, related to OxLDL downregulation of GAPDH, may play an important role in mechanisms of atherogenesis.
